With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Weight loss drugmaker Novo Nordisk ... NVO said the leadership transition was made in light of the company’s recent market challenges and the performance of its stock since mid-2024.

Adventurous speculators interested in a quick-strike opportunity may want to set their sights on Novo Nordisk (NYSE: NVO ).

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

Novo Nordisk and its chief executive are parting ways after recent market challenges and a sharp decline in the company's share price over the past 12 ... This Stock Is Cheap, High-Yielding, ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

Novo Nordisk has a GLP-1 Ozempic pill. That's both good and bad news for Novo Nordisk stock. Skip to main content. Boydton, VA. Boydton, VA. Local News. Subscriptions; Animals. Finance ...

Novo Nordisk and its chief executive are parting ways after recent market challenges and a sharp decline in the company's share price over the past 12 months. Lars Fruergaard Jorgensen, who has ...